文献速递肺外科

M1a-IVA期非小细胞肺癌原发肿瘤手术治疗的回顾性队列研究

Surgical management of the primary tumor in stage M1a-IVA non-small cell lung cancer.
PubMed 文献 · J Thorac Cardiovasc Surg · 2026-05-02

该回顾性队列研究纳入2007年2月至2024年4月北京大学肿瘤医院145例M1a-IVA期非小细胞肺癌患者,采用逆概率加权平衡基线特征。56例接受原发肿瘤切除,术后并发症12.5%且无≥3级事件;手术组5年总生存显著高于非手术组(51.3% vs 32.6%,P=.003)。多因素分析显示无经典EGFR突变或ALK融合、2018年前诊断及未行原发肿瘤切除与更差总生存相关。

要点

  • M1a-IVA期NSCLC原发肿瘤切除术后并发症12.5%,无≥3级事件。
  • 手术组5年总生存51.3%,非手术组32.6%(P=.003)。
  • 扩大肺切除范围或系统淋巴结清扫未显示额外生存获益。

核心结论

  • 在高选择性的M1a-IVA期非小细胞肺癌患者中,原发肿瘤切除可行,并可能与有利的生存结局相关。

研究设计与样本

  • 回顾性队列研究,纳入2007年2月至2024年4月北京大学肿瘤医院145例M1a-IVA期非小细胞肺癌患者,采用逆概率加权平衡基线特征。

主要发现

  • 56例接受原发肿瘤切除,其中12例术前接受系统治疗;术式包括肺叶切除27例、亚肺叶切除25例、全肺切除1例。
  • 平均手术时间104.49分钟,平均出血量75.66 mL,平均术后住院5.25天。
  • 术后并发症发生率12.5%(7/56),无≥3级事件。
  • 手术组5年总生存显著高于非手术组(51.3% vs 32.6%,P=.003)。
  • 多因素分析显示无经典EGFR突变(19del/L858R)或ALK融合、2018年前诊断及未行原发肿瘤切除与更差总生存相关。

关键数值与推荐

  • 亚组分析显示更广泛的肺切除或系统淋巴结清扫未带来额外生存获益。

临床怎么用

  • 对于高度选择的M1a-IVA期非小细胞肺癌患者,原发肿瘤切除可作为个体化治疗选项,需结合分子分型与诊断年份综合评估。

局限性

  • 回顾性研究设计,样本量有限(145例),手术组经过高度选择,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Stage M1a-IVA non-small cell lung cancer has traditionally been regarded as an advanced disease primarily managed with systemic therapy, and the role of surgical intervention remains controversial. This study aimed to evaluate the safety of primary tumor resection in patients with stage M1a-IVA non-small cell lung cancer and its association with survival outcomes, as well as to explore its potential implications for real-world clinical decision-making. METHODS: This retrospective cohort study included patients with stage M1a-IVA non-small cell lung cancer treated at Peking University Cancer Hospital between February 2007 and April 2024. Both medically and surgically managed patients were drawn from the same treatment era. Clinicopathologic data were collected, and inverse probability of treatment weighting was applied to balance baseline characteristics. Survival differences were assessed using the Kaplan-Meier method, and independent prognostic factors were evaluated with Cox proportional hazards models. RESULTS: A total of 145 patients were included, with a mean age of 59.1 years. Adenocarcinoma accounted for 77.9% of cases (113/145), and 31.7% (46/145) harbored classic epidermal growth factor receptor mutations (19del/L858R) or anaplastic lymphoma kinase fusion. Fifty-six patients underwent primary tumor resection, including 12 who received systemic therapy before surgery. Surgical procedures consisted of lobectomy in 27 patients, sublobectomy in 25 patients, and pneumonectomy in 1 patient. The mean operative time was 104.49 minutes, with an average blood loss of 75.66 mL and a mean postoperative hospital stay of 5.25 days. Postoperative complications occurred in 12.5% of patients (7/56), with no grade 3 or higher events observed. Subgroup analysis demonstrated no additional survival benefit associated with more extensive lung resection or systematic lymph node dissection. The 5-year overall survival was significantly higher in the primary tumor resection group than in the nonresection group (51.3% vs 32.6%, P = .003). Multivariable analysis identified several factors associated with worse overall survival. These included absence of classic epidermal growth factor receptor mutations (19del/L858R) or anaplastic lymphoma kinase fusion, diagnosis before 2018, and no primary tumor resection. CONCLUSIONS: By comparing outcomes between patients managed with systemic therapy alone and those undergoing surgical intervention during treatment, this study suggests that primary tumor resection is feasible and may be associated with favorable survival outcomes in highly selected patients with stage M1a-IVA non-small cell lung cancer.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Fang Y, Fan M, Chen H, et al. Surgical management of the primary tumor in stage M1a-IVA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2026. PMID: 42081971. doi:10.1016/j.jtcvs.2026.04.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。